Member Posts > Cardiol Therapeutics' CRD-38 and Mitochondrial Dysfunction in Heart Failure
Mitochondrial dysfunction is a key driver of heart failure (HF), as it leads to impaired energy production, oxidative stress, and increased cell death. Cardiol Therapeutics is developing CRD-38, a novel cannabidiol (CBD)-based subcutaneous therapy, to target these mitochondrial deficiencies. CRD-38 leverages CBD's anti-inflammatory properties to reduce oxidative stress and preserve mitochondrial function. Additionally, it activates PPAR-γ, a crucial regulator of mitochondrial biogenesis, leading to improved ATP generation and cardiac efficiency. Preclinical studies have shown that CRD-38 enhances mitochondrial respiration, reduces oxidative damage, and improves overall cardiac output. With a focus on patients with HFpEF (heart failure with preserved ejection fraction), CRD-38 offers a promising therapeutic approach. Cardiol Therapeutics is actively progressing through regulatory steps to initiate clinical trials and validate its efficacy in human subjects.

#CardiolTherapeutics #HeartFailureTreatment #BiotechInvesting #ClinicalTrials #CBDTherapeutics #HeartHealth #MedicalInnovation #PharmaceuticalBreakthroughs #CRD38